Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal serogroup B vaccine
- Development stage
- Preclinical
- Lead developer
- Techinvention Lifecare
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
The meningococcal serogroup B vaccine is a recombinant protein vaccine being developed by Techinvention Lifecare for the prevention of meningococcal disease. It specifically targets *Neisseria meningitidis* serogroup B, a major cause of bacterial meningitis and sepsis. Unlike other meningococcal serogroups (A, C, W, Y) that can be effectively targeted with polysaccharide-based conjugate vaccines, serogroup B's capsular polysaccharide is structurally similar to human neural cell adhesion molecules, making it poorly immunogenic and posing a risk of autoimmunity. To overcome this, the vaccine utilizes recombinant protein antigens to stimulate a protective immune response. The candidate is currently in the preclinical stage of development.
- Other names
- Neisseria meningitidis serogroup B recombinant protein vaccine
Beyond the preview
Go deeper on meningococcal serogroup B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal serogroup B vaccine.